ImmuCell vs Alpha Teknova
ICCC and TKNO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ICCC and TKNO compare
Alpha Teknova is the larger company, worth 5.0 times as much as ImmuCell ($463M against $92.5M).
Alpha Teknova grew revenue faster over the last twelve months (15.4% versus 8.5% for ImmuCell).
ImmuCell keeps more of each dollar of sales as profit, with a net margin of 2.6% compared with −34.8% at Alpha Teknova.
ImmuCell scores higher on the StockData Score (14 against 12 for Alpha Teknova), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ICCC | TKNO |
|---|---|---|
| Size and price | ||
| Market cap | $92.5M | $463M |
| Share price | $10.19 | $8.62 |
| Change, 1 year | 67.6% | 87.0% |
| Change, 5 years | 15.3% | −65.5% |
| Beta (5Y) | 0.10 | 1.19 |
| Employees | 73 | 158 |
| StockData Score | ||
| Total score | 14 (better) | 12 |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 | 3 |
| Performance score | 4 (better) | 3 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 127× | – |
| P/S | 3.0× (better) | 10.1× |
| P/B | 2.9× (better) | 7.7× |
| EV/EBITDA | 14.6× | – |
| P/FCF | 22.0× | – |
| FCF yield | 4.6% (better) | −1.4% |
| Fair value | $11.19 | $3.45 |
| Margin of safety | 8.9% (better) | −150% |
| Growth | ||
| Revenue growth (TTM) | 8.5% | 15.4% (better) |
| Revenue growth, 5Y average | 12.5% (better) | 5.3% |
| Net income growth (TTM) | −55.3% | – |
| EPS growth (TTM) | −57.9% | – |
| Profitability | ||
| Gross margin | 40.3% (better) | 36.4% |
| Operating margin | 12.6% (better) | −32.7% |
| Net margin | 2.6% (better) | −34.8% |
| FCF margin | 13.7% (better) | −13.9% |
| Return on equity | 2.6% (better) | −24.1% |
| Return on invested capital | 11.1% (better) | −25.3% |
| Financial health | ||
| Debt / equity | 0.26 (better) | 0.00 |
| Net debt / EBITDA | −0.09 | – |
| Interest coverage | 8.9× | – |
| Current ratio | 4.75 (better) | 3.56 |
| Altman Z-score | 4.66 | 6.03 (better) |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 14.7% | 17.0% |
| Held by insiders | 13.6% | 1.3% |
| Insider net buying, 12 months | $156K (better) | $144K |
| Short interest, % of float | 0.19% | 2.9% |
Go deeper
- ICCC stock overview
- ICCC income statement
- ICCC valuation and score
- TKNO stock overview
- TKNO income statement
- TKNO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.